Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DPT Laboratories has received FDA approval to manufacture commercial supplies of a sterile ointment for wound care at its Center of Excellence for Sterile & Specialty Products in Lakewood.
Subscribe to our email newsletter
Healthpoint will ship commercial lots of Collagenase Santyl Ointment produced at DPT’s Lakewood facility to its North American customers, beginning this month.
DPT’s Sterile & Specialty Products center focuses on aseptic production of sterile dosage forms to include small-volume parenterals, ophthalmic preparations, preservative-free nasal sprays and sterile ointments.
The company will begin manufacturing small-volume parenterals and additional ophthalmic preparations in early 2011 and expects to successfully complete several site transfers and new product launches over the next 24 months.
Healthpoint president and CEO Travis Baugh said that the recent FDA approval of DPT’s Lakewood facility to produce Collagenase Santyl Ointment allows Healthpoint to immediately double its production capacity, thereby helping assure continuous, uninterrupted supply for this important therapeutic agent.